Relationship between hydroxychloroquine blood levels and lupus activity through the lens of the type 1 and type 2 lupus model: a cross-sectional study
Introduction In the type 1 and 2 SLE model, inflammation mediates type 1 manifestations, but its role in type 2 manifestations (eg, fatigue, myalgias, mood disturbance, cognitive dysfunction) is less clear. Therapeutic hydroxychloroquine (HCQ) levels reduce type 1 activity, but their relationship wi...
Saved in:
| Main Authors: | Rebecca E Sadun, Kai Sun, Amanda M Eudy, Megan E B Clowse, Roberta Vezza Alexander, Stephen J Balevic, Lisa G Criscione-Schreiber, Mithu Maheswaranathan, Jennifer L Rogers, Jayanth Doss, Tyler O’Malley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001531.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model
by: Amanda M. Eudy, et al.
Published: (2024-12-01) -
Development and implementation of a virtual Lupus Patient Education Event during the COVID-19 pandemic
by: Diane L Kamen, et al.
Published: (2021-04-01) -
Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?
by: Guillermo Ruiz-Irastorza, et al.
Published: (2025-04-01) -
Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
by: John Conklin, et al.
Published: (2019-12-01) -
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
by: Alberto Floris, et al.
Published: (2018-01-01)